On July 15, Cardiac Medical announced that the Aorfix™ abdominal aortic laminating stent system, a product in the field of interventional treatment of abdominal aortic diseases developed by its European subsidiary Lombard Medical Co., Ltd., was officially approved to enter the China Drug Administration's special review process for innovative medical devices.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.